top of page

CAR-T Eligibility 

Axicabtagene Ciloleucel in 3rd Line large B-cell lymphomas

adusumillia-car_0_3x2 (1).webp

These eligibility criteria for CAR-T are based on the revised Cancer Drugs Fund List published following the exit of Axicel from the CDF to baseline commissioning. 

The criteria have evolved since the initial CDF listing, and include new indications such as concurrent CNS disease and PTLD.

The below is intended as a guide to referring centres in assessing potential eligibility for CAR-T. However, it is strongly recommended that patients potentially eligible for CAR-T are discussed urgently with a CAR-T physician at UHS. 

Eligibility Assessment for Axicel in 3rd Line Large B-cell Lymphoma

•Refractory disease is defined as either progressive disease as the best response to the last line of systemic therapy or stable disease as the best response after at least 2 cycles of the last line of therapy with stable disease duration lasting no longer than 6 months from the last dose of the last line of systemic therapy.

•Relapsed disease is defined as disease that responded partially or completely to the last line of therapy and has since progressed.

•Progressive disease should be defined radiologically as per RECIST version 1.1 and be based on CT or MR scans and aided if necessary, after discussion at the NCCP, with the use of Lugano lymphoma response criteria.

•Second line treatment regimens which are appropriate include: R-GDP, R-GemOx, R-GemCarbo, R-ESHAP, R-ICE, R-IVE, R-IVAC, R-BendaPola and the Marietta protocol (e.g. 3xMATRix).

•Neither radiotherapy nor steroids can be counted as a line of therapy

Age

18+ or

post-pubescent (off licence)

Diagnosis

• DLBCL

• PMBL

• Transformed FL/MZL/CLL/NLPHL to DLBCL

• PTLD, DLBCL type (EBV neg or pos)

• FL grade 3B

AND

Previously treated with at least three cycles of a full-dose anthracycline containing regimen (e.g. CHOP) or at least three cycles on MARIETTA protocol (e.g. 3xMATRix), or 2 cycles if clear progression.

 

AND

Previously treated with at least one anti-CD20 antibody (e.g. ritux/obinu) unless demonstrated to have CD20 negative disease

 

AND

If previously treated with CD19 directed therapy, is demonstrated to still have CD19 positive disease at the point of referral for CAR-T

 

AND

Has not previously been treated with genetically modified T-cell therapy, except in an abandoned dosing cohort in a first in human dose-escalation phase I clinical trial

Biopsy

• Re-biopsy at first relapse has confirmed DLBCL or PMBCL and the patient has progressive disease at the same site or

• Re-biopsy at second relapse has confirmed DLBL or PMBCL or

• Re-biopsy at first or second relapse was/is unsafe plus there is progressive disease at previously documented sites of active disease and the previous histology was DLBCL or PMBCL or

• Re-biopsy at second relapse has again confirmed transformed lymphoma (TFL, MZL, CLL, NLPHL) to DLBCL or

• Re-biopsy at second relapse has again confirmed PTLD of DLBCL type or

• Re-biopsy at second relapse has again confirmed FL grade 3B

Clinical Scenario

one of...

• Has DLBCL and received 2 or more lines of systemic therapy and relapsed after or was refractory to the last line of systemic therapy or

• Had DLBCL with CNS involvement at first diagnosis and treated with first line systemic therapy (eg Marietta protocol) followed by stem cell transplantation as part of first line therapy and has relapsed after or was refractory to this first line of systemic therapy or

• Has PMBCL and received 2 or more lines of systemic therapy and relapsed after or was refractory to the last line of systemic therapy or

• Has transformed lymphoma to DLBCL (TFL, MZL, CLL, NLPHL) and received 2 or more lines of systemic therapy since diagnosis of transformation and relapsed after or was refractory to the last line of systemic therapy or

• Has transformed lymphoma to DLBCL (TFL, MZL, NLPHL), received an anthracycline-containing regimen before transformation, and after transformation then received 1 or more lines of systemic therapy and relapsed after or was refractory to the last line of systemic therapy or

• Has PTLD of DLBCL type and received 2 or more lines of systemic therapy since diagnosis of PTLD of DLBCL type and relapsed after or was refractory to the last line of systemic therapy or

• Has FL grade 3B and received 2 or more lines of systemic therapy and relapsed after or was refractory to the last line of systemic therapy

CNS disease

• Has no known CNS involvement or

• Has both CNS and systemic disease

Note: patients with current isolated CNS involvement are not eligible

Performance status and organ function

• Has ECOG performance status of 0 or 1, accounting for pre-existing or disease-related neurodisability.

• Has sufficient end organ function to tolerate treatment with CAR-T cell therapy

bottom of page